Press Releases


  • HeartFlow Analysis Demonstrates Highest Diagnostic Performance for Detecting Heart Disease Compared to Other Non-Invasive Tests. PDF
  • NHS England to Provide Innovation and Technology Payment (ITP) to Drive Adoption of HeartFlow Analysis in the United Kingdom. PDF
  • HeartFlow Announces Collaborative Research Agreement with Imperial College London. PDF
  • HeartFlow Enters into Licensing Agreement with Cedars-Sinai for Coronary Plaque Assessment Technology. PDF
  • HeartFlow Completes Series E Financing, Securing $240 Million. PDF


  • Philips and HeartFlow Announce Global Collaboration Agreement. PDF
  • GE Healthcare and HeartFlow Announce Global Cardiovascular Collaboration. PDF
  • HeartFlow Names Former J&J Chairman and CEO William C. Weldon Chairman of the Board. PDF
  • HeartFlow Names Healthcare Industry Veteran Michael Buck as Executive Vice President and Chief Commercial Officer. PDF
  • Siemens Healthineers and HeartFlow Collaborate to Provide Solution That Has Potential to Lower Cardiac Care Costs. PDF
  • NICE Guidance Recommends HeartFlow FFRCT Analysis to Help Determine Cause of Stable Chest Pain in Patients. PDF


  • HeartFlow FFRCT Analysis Receives Regulatory Approval in Japan. PDF
  • Providence Health Care Becomes First Canadian Center to Adopt Revolutionary HeartFlow FFRCT Analysis to Assess Coronary Artery Disease. PDF
  • HeartFlow Introduces Next Generation Platform. PDF
  • Technology from HeartFlow Provides Insights to Help Identify Coronary Plaques at Risk of Rupturing. PDF
  • Highmark Health’s VITAL program partners with Allegheny Health Network and HeartFlow to evaluate a novel 3D technology. PDF
  • One-Year PLATFORM Trial Results Reinforce Benefits of the HeartFlow FFRCT Analysis for Assessing Coronary Artery Disease. PDF


  • Trial Demonstrates HeartFlow FFRCT Analysis Significantly Lowers Cost of Care, Improves Quality of Life for Coronary Artery Disease. PDF
  • HeartFlow Secures 50th U.S. Patent. PDF
  • PLATFORM Trial Shows HeartFlow FFRCT Analysis Significantly Decreases Unnecessary Invasive Diagnostic Testing for Coronary Artery Disease. PDF
  • Technology Industry Veteran Phil Mui Joins HeartFlow Product & Engineering Team. PDF
  • EuroPCR Late-breaking Trial: FFRCT RIPCORD Study Demonstrates the Impact of HeartFlow FFRCT Analysis on Patient Management. PDF
  • Kent Walker Joins HeartFlow Board of Directors. PDF


  • HeartFlow Names New General Counsel to Executive Team. PDF
  • HeartFlow Appoints Former Johnson & Johnson Chairman and CEO William C. Weldon to Board of Directors. PDF
  • HeartFlow Secures De Novo Clearance from the U.S. Food and Drug Administration for Breakthrough FFRCT Technology. PDF
  • HeartFlow Announces Appointment of Several Key Executive Hires. PDF


  • Landmark Study of HeartFlow’s New Non-Invasive Diagnostic Test Demonstrates High Diagnostic Performance in Patients with Suspected Coronary Artery Disease. PDF


  • EuroPCR Innovation Award. PDF